Who we are
Measurement and modulation of the gut microbiome in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way.
Enterome is pioneering the development of novel diagnostic products to support personalized therapies and the clinical development of new drugs in microbiome-related diseases.
Our unique Metagenotyping® process addresses an unmet need to develop specific biomarkers with clinical utility for treatment response prediction, disease activity monitoring and use as companion diagnostics (CDx).
Metagenotyping® has already been successfully used by Enterome for biomarker discovery and patient stratification in various microbiome related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.
Enterome is leading the development of new industry standards in gut microbiome quantitative and functional analysis. Opening up a new field of therapeutic targets discovery in the microbiome and allowing the innovative repositioning of existing compounds targeting this new organ.
Interview “3 minutes pour la Santé“3 February 2014
The Marie Curie IAPP project “Industria-Academia exchange to further FXR-based therapeutic intervention and non-invasive diagnosis in Inflammatory Bowel Disease”,...1 January 2014